The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Zacks.com on MSN3h
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema CandidateIntellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback